Vadimezan

Vadimezan (pronounced vah-dih-MEH-zan) is a small molecule inhibitor that was developed for the treatment of cancer. It is also known by its chemical name, DMXAA (5,6-dimethylxanthenone-4-acetic acid).

Etymology

The name "Vadimezan" is a proprietary name given by the pharmaceutical company that developed it. The chemical name, DMXAA, is an abbreviation of the chemical structure of the drug.

Pharmacology

Vadimezan is a type of drug known as a vascular disrupting agent. It works by disrupting the blood vessels that supply tumors, causing the tumors to starve and die. It is not a chemotherapy drug, but it is often used in combination with chemotherapy to enhance its effects.

Clinical Trials

Vadimezan has been tested in several clinical trials for various types of cancer, including lung cancer, melanoma, and kidney cancer. However, it has not yet been approved by the Food and Drug Administration (FDA) for use in the United States.

Related Terms

• Inhibitor
• Cancer
• Chemotherapy
• Clinical trials
• Food and Drug Administration

External links

• Medical encyclopedia article on Vadimezan
• Wikipedia's article - Vadimezan

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski